Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)
about
Effects of renal replacement therapy on plasma lipoprotein(a) levels.Lipoprotein(a) accelerates atherosclerosis in uremic mice.Epidemiology, pathophysiology and therapeutic implications of lipoprotein(a) in kidney disease.Association between high molecular weight apolipoprotein isoforms and lipoprotein levels in advanced chronic kidney disease and the effect of hemodialysis.Lipoprotein (a): impact by ethnicity and environmental and medical conditionsLipoprotein kinetics in male hemodialysis patients treated with atorvastatin.Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urineLipoprotein(a): resurrected by genetics.Causes and consequences of lipoprotein(a) abnormalities in kidney disease.Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis.Lipoprotein(a) in health and disease.Serum lipoprotein(a) concentrations and apolipoprotein(a) phenotypes in hemodialysis, chronic ambulatory peritoneal dialysis and post-transplant patients.Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation.Standardization and clinical management of lipoprotein(a) measurements.Discrepancy of interleukin-6 levels between end-stage renal disease patients and patients with acute-phase response with increased lipoprotein(a) concentrations.The role of lipoprotein (a) in chronic kidney disease.Effects of nandrolone decanoate (Decadurabolin) on serum Lp(a), lipids and lipoproteins in women with postmenopausal osteoporosis.
P2860
Q30437424-9ED552A5-CA71-49EF-843E-C8C6A8E3FC3FQ34116300-46949EF0-B2F0-4005-B459-F375FCE80246Q35879090-EA95CC2C-2609-4D0D-BA1E-D1E4C3A3451FQ36752445-F7F0109E-21A6-4F7E-BCA6-5CA4DD0E5EB8Q37033161-6F1B3552-89D5-49E8-B658-D875004FD41AQ37065629-8C64EEA6-7102-41A9-8836-B21599F58B5FQ37361631-C59B02B6-AFF4-499A-89A3-469A49409341Q38045424-9C69AB69-17B6-4418-B223-5F1E2027899DQ38152960-9DBBC619-4FAA-4D30-80AE-CDBE51C8820FQ41167018-F174F294-93F9-44EA-8F9A-AAD3E0266E47Q41300659-48B26C4E-F2BB-4EF1-8725-D9ACC00B4D57Q44032741-FCDAB073-CE45-4F50-9DC7-1F1593AF1503Q44562485-8D62BA3E-D693-45C2-9B69-ACFD263EA677Q44562856-BC0E7158-D31A-4581-9AE6-EA5957512CAAQ47276539-63A423A3-768F-4D8F-96A0-3B29B112EEE4Q49598174-4A7302FD-81F1-4581-9EFE-0CBE17416E40Q50927466-4F5224A7-22AF-4B11-9337-C55F71B6E8AF
P2860
Elevated plasma concentrations of lipoprotein(a) in patients with end-stage renal disease are not related to the size polymorphism of apolipoprotein(a)
description
1993 nî lūn-bûn
@nan
1993 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1993 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1993年の論文
@ja
1993年論文
@yue
1993年論文
@zh-hant
1993年論文
@zh-hk
1993年論文
@zh-mo
1993年論文
@zh-tw
1993年论文
@wuu
name
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@ast
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@en
type
label
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@ast
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@en
prefLabel
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@ast
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@en
P2093
P2860
P356
P1476
Elevated plasma concentrations ...... ymorphism of apolipoprotein(a)
@en
P2093
Dieplinger H
Hoppichler F
Kronenberg F
Sandholzer C
P2860
P304
P356
10.1172/JCI116213
P407
P577
1993-02-01T00:00:00Z